CD105 Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-CD105 antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD105 |
| Clone | polyclonal |
| Host Species | Rabbit |
| Reactive Species | human |
| Isotype | n/a |
| Format | immunogen affinity purified |
| Size | 0.1 mg |
| Concentration | n/a |
| Applications | Western Blot (WB), Immunohistochemistry (IHC) Paraffin |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Description: Rabbit IgG polyclonal antibody for Endoglin(ENG) detection. Tested with WB, IHC-P in Human. Background: Endoglin(Osler-Rendu-Weber syndrome 1), CD105, is a type I membrane glycoprotein located on cell surfaces and is a part of the TGF beta receptor complex. Its gene is mapped to human chromosome 8. The protein consists of a homodimer of 180 kDA with disulfide links. It has been found on endothelial cells, activated macrophages, fibroblasts and smooth muscle cells. Endoglin has a role in the development of the cardiovascular system and in vascular remodeling and has been found to be elevated in pregnant women who subsequently develop preeclampsia. |
| Immunogen | Immunogen: A synthetic peptide corresponding to a sequence at the N-terminus of human CD105 (26-44aa ETVHCDLQPVGPERGEVTY). |
| Other Names | [Endoglin; endoglin; CD 105; CD105; CD105 antigen; EGLN_HUMAN; END; Endoglin; ENG; FLJ41744; HHT1; ORW; ORW1; Osler Rendu Weber syndrome 1; RP11 228B15.2; SN6], [ENG; ENG; END; HHT1; ORW1; END] |
| Gene, Accession # | [ENG], Gene ID: 2022, NCBI: P17813.2, UniProt: P17813 |
| Catalog # | MBS175174 |
| Price | $315 |
| Order / More Info | CD105 Antibody from MYBIOSOURCE INC. |
| Product Specific References | n/a |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies